Irene Campi1, Maura Agostini2, Federica Marelli1, Tiziana de Filippis1, Beatriz Romartinez-Alonso3, Odelia Rajanayagam2, Giuditta Rurale1, Ilaria Gentile4, Federica Spagnolo5, Massimiliano Andreasi6, Francesco Ferraù5,7, Salvatore Cannavò5,7, Laura Fugazzola1,8, Krishna V Chatterjee2, Luca Persani1,4. 1. Division of Endocrine and Metabolic Diseases and Laboratory of Endocrine and Metabolic Research, Istituto Auxologico Italiano, Istituto Di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy. 2. Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, United Kingdom. 3. Department of Molecular and Cell Biology, Leicester Institute of Structural and Chemical Biology, University of Leicester, Leicester, United Kingdom. 4. Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy. 5. Unit of Endocrinology, University Hospital "G. Martino", Messina, Italy. 6. Laboratorio Analisi Cliniche, Centro di Ricerche e Tecnologie Biomediche, IRCCS Istituto Auxologico Italiano, Cusano Milanino, Italy. 7. Department of Human Pathology of Adulthood and Childhood, University of Messina, Messina, Italy. 8. Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
Abstract
INTRODUCTION: Resistance to thyroid hormone β (RTHβ) is an inherited syndrome caused by dominant negative variants in the THRB gene (NM_000461.5). The clinical picture of RTHβ is variable, and patients harboring the same variant may display different degrees of disease severity. CASE PRESENTATION: A 30-year-old man presented with thyrotoxicosis and central hyperthyroidism and was found to have a novel variant in the exon 10 of THRB gene (c.C1282G, p.L428V), located within the third hot spot region of the C-terminal of the receptor. Surprisingly, the same variant was found in two other relatives with an apparent normal thyroid function at initial screening. After exclusion of a TSH-secreting adenoma and serum interference in the proband, and the finding that exogenous levothyroxine failed to suppress the TSH in the brother affected by nodular goiter, relatives' thyroid function tests (TFTs) were reassessed with additional analytical method revealing biochemical features consistent with RTHβ in all carriers of the p.L428V variant. Functional studies showed a slightly impaired in vitro transcriptional activity of p.L428V. Interestingly' the expression of the human p.L428V thyroid hormone receptor beta in the zebrafish embryo background generated a phenotype consistent with RTHβ. CONCLUSION: Variable results of TFTs on some immunoassays can be a cause of RTHβ diagnostic delay, but the genotype-phenotype correlation in this family and functional studies support p.L428V as a novel THRB variant expanding the spectrum of gene variants causing RTHβ. In vivo, rather than in vitro, functional assays may be required to demonstrate the dominant negative action of THRB variants.
INTRODUCTION: Resistance to thyroid hormone β (RTHβ) is an inherited syndrome caused by dominant negative variants in the THRB gene (NM_000461.5). The clinical picture of RTHβ is variable, and patients harboring the same variant may display different degrees of disease severity. CASE PRESENTATION: A 30-year-old man presented with thyrotoxicosis and central hyperthyroidism and was found to have a novel variant in the exon 10 of THRB gene (c.C1282G, p.L428V), located within the third hot spot region of the C-terminal of the receptor. Surprisingly, the same variant was found in two other relatives with an apparent normal thyroid function at initial screening. After exclusion of a TSH-secreting adenoma and serum interference in the proband, and the finding that exogenous levothyroxine failed to suppress the TSH in the brother affected by nodular goiter, relatives' thyroid function tests (TFTs) were reassessed with additional analytical method revealing biochemical features consistent with RTHβ in all carriers of the p.L428V variant. Functional studies showed a slightly impaired in vitro transcriptional activity of p.L428V. Interestingly' the expression of the human p.L428V thyroid hormone receptor beta in the zebrafish embryo background generated a phenotype consistent with RTHβ. CONCLUSION: Variable results of TFTs on some immunoassays can be a cause of RTHβ diagnostic delay, but the genotype-phenotype correlation in this family and functional studies support p.L428V as a novel THRB variant expanding the spectrum of gene variants causing RTHβ. In vivo, rather than in vitro, functional assays may be required to demonstrate the dominant negative action of THRB variants.
Authors: Bernard W Steele; Edward Wang; George G Klee; Linda M Thienpont; Steven J Soldin; Lori J Sokoll; William E Winter; Susan A Fuhrman; Ronald J Elin Journal: Arch Pathol Lab Med Date: 2005-03 Impact factor: 5.534
Authors: Y Hayashi; R E Weiss; D H Sarne; P M Yen; T Sunthornthepvarakul; C Marcocci; W W Chin; S Refetoff Journal: J Clin Endocrinol Metab Date: 1995-11 Impact factor: 5.958
Authors: Samuel Refetoff; J H Duncan Bassett; Paolo Beck-Peccoz; Juan Bernal; Gregory Brent; Krishna Chatterjee; Leslie J De Groot; Alexandra M Dumitrescu; J Larry Jameson; Peter A Kopp; Yoshiharu Murata; Luca Persani; Jacques Samarut; Roy E Weiss; Graham R Williams; Paul M Yen Journal: Thyroid Date: 2014-03-04 Impact factor: 6.568
Authors: Sue Richards; Nazneen Aziz; Sherri Bale; David Bick; Soma Das; Julie Gastier-Foster; Wayne W Grody; Madhuri Hegde; Elaine Lyon; Elaine Spector; Karl Voelkerding; Heidi L Rehm Journal: Genet Med Date: 2015-03-05 Impact factor: 8.822